Literature DB >> 25199867

Chitosan as a suitable nanocarrier material for anti-Alzheimer drug delivery.

Jayrajsinh Sarvaiya1, Y K Agrawal2.   

Abstract

Chitosan, a biocompatible natural polysaccharide is frequently reported carrier material in targeted drug delivery to treat neurodegenerative disorders. Chitosan and its biodegradable products exert its bioactivities on nerve cells and blood brain barrier at the molecular level, which are beneficial in anti-Alzheimer therapy. Flexibility of surface modification, the ability to get attached with varieties of ligand molecules and the formation of the stable nano complex in physiological condition make chitosan an adorable material for delivery of anti-Alzheimer drugs and siRNA to the brain. The success rate of nose to brain delivery of anti-Alzheimer drugs enhances when chitosan used as a carrier material. This review covers direct and indirect anti-Alzheimer effects of chitosan, surface modification strategies to augment permeation from the blood-brain barrier structure, different ligands reported for brain targeting of chitosan nanoparticles containing anti Alzheimer drugs, blood compatibility and widely utilized chitosan nanoparticle fabrication techniques. Key intellectual claims are also condensed through patents to appraise chitosan as an attractive polymer for brain targeted nanoformulation which is currently facing oversight by regulatory agencies and manufacturers.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Alzheimer's disease; Anti-Alzheimer drugs; Brain targeting; Chitosan

Mesh:

Substances:

Year:  2014        PMID: 25199867     DOI: 10.1016/j.ijbiomac.2014.08.052

Source DB:  PubMed          Journal:  Int J Biol Macromol        ISSN: 0141-8130            Impact factor:   6.953


  15 in total

1.  Protective effect of controlled release of cytokine response modifier A from chitosan microspheres on rat chondrocytes from interleukin-1β induced inflammation and apoptosis.

Authors:  Pang-Hu Zhou; Lei Shi; Bo Qiu
Journal:  Exp Ther Med       Date:  2017-08-03       Impact factor: 2.447

2.  Treatment of Dutch rat models of glioma using EphrinA1-PE38/GM-CSF chitosan nanoparticles by in situ activation of dendritic cells.

Authors:  Ming Li; Bin Wang; Zhonghua Wu; Xiwen Shi; Jiadong Zhang; Shuangyin Han
Journal:  Tumour Biol       Date:  2015-05-10

Review 3.  Protective Effects of Polysaccharides in Neurodegenerative Diseases.

Authors:  Yinying Wang; Rongsha Chen; Zhongshan Yang; Qian Wen; Xia Cao; Ninghui Zhao; Jinyuan Yan
Journal:  Front Aging Neurosci       Date:  2022-07-04       Impact factor: 5.702

4.  Brain targeted oral delivery of doxycycline hydrochloride encapsulated Tween 80 coated chitosan nanoparticles against ketamine induced psychosis: behavioral, biochemical, neurochemical and histological alterations in mice.

Authors:  Monu Yadav; Milind Parle; Nidhi Sharma; Sameer Dhingra; Neha Raina; Deepak Kumar Jindal
Journal:  Drug Deliv       Date:  2017-11       Impact factor: 6.419

5.  Zinc-Modified Nanotransporter of Doxorubicin for Targeted Prostate Cancer Delivery.

Authors:  Sylvie Skalickova; Martin Loffelmann; Michael Gargulak; Marta Kepinska; Michaela Docekalova; Dagmar Uhlirova; Martina Stankova; Carlos Fernandez; Halina Milnerowicz; Branislav Ruttkay-Nedecky; Rene Kizek
Journal:  Nanomaterials (Basel)       Date:  2017-12-08       Impact factor: 5.076

Review 6.  Smart Carriers and Nanohealers: A Nanomedical Insight on Natural Polymers.

Authors:  Sreejith Raveendran; Ankit K Rochani; Toru Maekawa; D Sakthi Kumar
Journal:  Materials (Basel)       Date:  2017-08-10       Impact factor: 3.623

Review 7.  Perspective highlights on biodegradable polymeric nanosystems for targeted therapy of solid tumors.

Authors:  Marziyeh Fathi; Jaleh Barar
Journal:  Bioimpacts       Date:  2017-02-20

Review 8.  Oral and Intra-nasal Administration of Nanoparticles in the Cerebral Ischemia Treatment in Animal Experiments: Considering its Advantages and Disadvantages.

Authors:  Firoozeh Alavian; Nasrin Shams
Journal:  Curr Clin Pharmacol       Date:  2020

9.  Designing Novel Nanoformulations Targeting Glutamate Transporter Excitatory Amino Acid Transporter 2: Implications in Treating Drug Addiction.

Authors:  Pss Rao; Murali M Yallapu; Youssef Sari; Paul B Fisher; Santosh Kumar
Journal:  J Pers Nanomed       Date:  2015-07-27

10.  Recombinant pre-miR-29b for Alzheimer´s disease therapeutics.

Authors:  Patrícia A Pereira; Joana F Tomás; João A Queiroz; Ana R Figueiras; Fani Sousa
Journal:  Sci Rep       Date:  2016-01-28       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.